Therapeutic Advances in Psychopharmacology was launched in 2011 to provide clinicians and researchers in psychopharmacology a platform to publish their findings in a free-to-read format, thereby offering a universal access to latest information in the field. Since then, interest in open access (OA) publishing has greatly grown, and the journal will become fully gold OA from the beginning of 2019. Moreover, important advances have recently been made in giving authors and peer reviewers the credit they deserve for their contributions, as well as measuring the impact of research beyond citations.
Get kudos for your research and peer review activities
With 2.5 million articles being published each year, it is important to facilitate the discovery of research articles to maximise visibility, usage and citation. SAGE has partnered with Kudos, a third-party service that allows authors to explain, enrich and share their articles, and then measure the impact of their actions. You can find out more information about how to engage with your audience on the SAGE Journal author gateway. Moreover, SAGE has created a resource for authors to disseminate their articles in social media.
Although many authors still consider journal Impact Factor as important when choosing a journal to publish in, alternative, non-citation-based metrics are gaining momentum. These differ primarily in that they are article metrics rather than journal metrics, and measure the impact of the research mostly by assessing social media coverage. The increasing mobility between institutions necessitates a way of having an authenticated record of contribution to the scientific community as an author and peer reviewer. Authors of Therapeutic Advances in Psychopharmacology are encouraged to use ORCID ID, a persistent digital identifier that distinguishes researchers from each other. ORCID is a non-profit organisation, and an ORCID ID is free to obtain.
Peer reviewers of the journal can now also get official credit for their contribution to the journal via Publons (www.publons.com). All reviewers are encouraged to register and create a reviewer profile at Publons, and they can opt in for receiving credit for their review when completing the peer review proces. Therapeutic Advances in Psychopharmacology can authenticate a reviewer automatically and, since Publons only publishes the year of the review and the journal title within the reviewer profiles, there is no breach of the journals' single-blinded peer review system.
Advances in Open Access
Free access to research facilitates wider dissemination of latest research and clinical knowledge, as many clinicians and researchers -particularly those who work in developing countries -do not have an institutional access to journals and are The push towards OA publishing has been from government and research funders, as well as from the OA advocates within the scientific community, who argue that the availability of research results to all will speed up the progress of research and that if the taxpayer has paid for the research, they have the right to see the results. Some funders now require immediate access to the work at the point of publication, which is the Gold OA route. OA, as opposed to Free to View (Table 1) , also requires an open copyright license of Creative Commons (CC).
Novel developments in
The most notable initiative towards OA is the Plan S, announced in September 2018 by the cOAlition S, a group of European national research funding organisations supported by the European Commission and the European Research Council (ERC). The key principle of the Plan S is that by 1 January 2020, all scientific publications on the results from research funded by the cOAlition S must be published in compliant OA journals or on compliant OA platforms.
Although the hybrid model is still the most common model to publish articles OA, some funders -including the cOAlition S -require that research that they fund is published in journals that are fully gold OA, rather than in hybrid OA/ subscription journals. Moreover, some argue that it is not fair for a hybrid journal to obtain funding from subscriptions and at the same time to obtain 
